Showing 2301-2310 of 5696 results for "".
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-ga-secondary-to-dry-amd/2481472/Cognition Therapeutics announced that its investigational new drug (IND) application for CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been cleared by the FDA. Cognition plans to initiate the phase 2 MAGNIFY trial of its oral drug candidate&nb
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Grifols Enters Into Global Collaboration and Licensing Agreement with Selagine to Develop Immunoglobulin Eye Drops to Treat Dry Eye Diseasehttps://modernod.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/Spanish pharma company Grifols announced a global collaboration and licensing agreement with Selagine to treat dry eye disease (DED) with immunoglobulin eye drops. Financial terms of the deal were not disclosed. The potential immunoglobulin treatment would be G
- Ace Vision Group Appoints Cristos Ifantides, MD, as Director, Clinical Applications Developmenthttps://modernod.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/Ace Vision Group (AVG) announced the appointment of Cristos Ifantides, MD, MBA, as Director, Clinical Applications Development, effective immediately. In his new role, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology
- EyePoint and Rallybio Partner to Evaluate Inhibitor of Complement Component 5 and Durasert Technology for Intraocular Delivery in GAhttps://modernod.com/news/eyepoint-and-rallybio-partner-to-evaluate-inhibitor-of-complement-component-5-and-durasert-technology-for-intraocular-delivery-in-ga/2481435/EyePoint Pharmaceuticals and Rallybio announced a research collaboration aimed at evaluating sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical
- Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Spacehttps://modernod.com/news/celanese-announces-a-research-agreement-with-johns-hopkins-university-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space/2481417/Specialty materials and chemical company Celanese announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. A bioinert implant based on the Celanese's VitalD
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Bausch + Lomb Launches Social Media Campaign Designed to Raise Awareness of AMDhttps://modernod.com/news/bausch-lomb-launches-social-media-campaign-designed-to-raise-awareness-of-amd/2481393/Bausch + Lomb announced a new social media campaign designed to raise awareness of age-related macular degeneration (AMD). The campaign, "What Sight Inspires You," will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educat
- SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-unveils-6-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481385/SpyGlass Pharma released 6-month data from a first-in-human glaucoma treatment trial showing that its drug delivery platform continues to demonstrate significant IOP lowering in patients with glaucoma or ocular hypertension, according to a company news release. The data were showcased d